Addressing the Threat of Drug-Resistant Tuberculosis A Realistic Assessment of the Challenge: Workshop Summary (2009) / Chapter Skim
Currently Skimming:
Appendix B: Participant Biographies
Appendix B: Participant Biographies
Pages 117-138
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 117... ...
Gail H Cassell, Ph.D., is currently Vice President, Scientific Affairs, and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company, Indianapolis, Indiana.
|
From page 118... ...
For 9 years she was chair of the Public and Scientific Affairs Board of the American Society for Microbiology; she has served as an advisor on infectious diseases and indirect costs of research to the White House Office of Science and Technology Policy, and has been an invited participant in numerous congressional hearings and briefings related to infectious diseases, antimicrobial resistance, and biomedical research. She has served two terms on the Liaison Committee on Medical Education (LCME)
|
From page 119... ...
Dr. Castro went on to complete his internal medicine postgraduate training in 1983 in the residency program in social medicine at the Montefiore Medical Center, Albert Einstein College of Medicine in New York.
|
From page 120... ...
and M.D. degrees from the University of Massachusetts, and trained in internal medicine and infectious diseases and epidemiology at the University of California, San Francisco, where he conducted research on the HIV epidemic in injection drug users and initiated early studies on the interaction of TB and HIV.
|
From page 121... ...
He was awarded the World Lung Health Award in 2006 by the American Thoracic Society for his scientific contributions to global control of pulmonary infections. Charles Daitch, Ph.D., is CEO of Akonni Biosystems Inc., which he founded in 2003.
|
From page 122... ...
In addition, he has served as a key advisor to the White House and the Department of Health and Human Services on global AIDS issues, and on initiatives to bolster medical and public health preparedness against emerging infectious disease threats such as pandemic influenza.
|
From page 123... ...
His group presented the first convincing evidence of lack of transmission of HIV by close personal contact, and defined the predictors of HIV transmission and natural history of HIV disease among injection drug users and the risk of reactivation of TB among those coinfected with HIV. More recently, Dr.
|
From page 124... ...
Neel Gandhi, M.D., is Assistant Professor of Medicine and Epidemiology at Albert Einstein College of Medicine and Montefiore Medical Center. He graduated from Brown Medical School and received training in primary care internal medicine at Columbia-Presbyterian Medical Center, clinical epidemiology in the Robert Wood Johnson Clinical Scholars Program at Yale University, and infectious diseases at Emory University.
|
From page 125... ...
She has served on multiple global health committees and is currently a member of the Board of Directors of the Aeras Global TB Vaccine Foundation. Anne Goldfeld, M.D., is Associate Professor of Medicine at Harvard Medical School, Senior Investigator at the Immune Disease Institute, Associate Professor of Immunology and Infectious Disease at the Harvard School of Public Health, and a member of the Infectious Disease Division at Brigham and Women's Hospital in Boston.
|
From page 126... ...
Mr. Harrington has been an ad hoc member of the FDA Antiviral Drugs Advisory Committee three times and served on the NIH AIDS Clinical Trials Group (ACTG)
|
From page 127... ...
Jim yong kim, M.D., Ph.D., holds appointments as François Xavier Bagnoud Professor of Health and Human Rights at the Harvard School of Public Health and Professor of Medicine and Social Medicine at Harvard Medical School. He is Chief of the Division of Global Health Equity at Brigham and Women's Hospital, a major Harvard teaching hospital; director of the François Xavier Bagnoud Center for Health and Human Rights; and Chair of the Department of Global Health and Social Medicine at Harvard Medical School.
|
From page 128... ...
kimerling, M.D., M.P.H., serves as a Senior Program Officer for TB in the Global Health Program at the Bill and Melinda Gates Foundation, working closely with established grantees and new partners on translational and operational research, and technology delivery issues urgently required to intervene in the global TB and MDR/XDR epidemics. Trained as an internist, he started his medical career working with nongovernmental organizations in refugee medicine and rebuilding primary health services in chronic conflict zones.
|
From page 129... ...
Moe, Ph.D., Executive in Residence, joined the Health Sector Management program, Fuqua School of Business, in 2001. His research interests include new incentives for innovation in neglected tropical and infectious disease research, private-sector responses to the global health care worker shortage, and the use of business intelligence as a basis for competitive advantage among life sciences firms.
|
From page 130... ...
tuberculosis strains, modeling the transmission dynamics of emerging infectious diseases, including MDR TB, West Nile virus, SARS, and various sexually transmitted diseases, human iron metabolism and tuberculosis susceptibility, identifying risk factors for the transmission of drug-sensitive and drug-resistant tuberculosis transmission using molecular and conventional epidemiologic methods, outcomes research in tuberculosis treatment and control programs, pedagogy in interdisciplinary research and emerging infectious disease, and exhaled particles and their relationship to infectivity of infectious agents. Carol A
|
From page 131... ...
, and serves on a number of committees in global health organizations. Prior to her business experience, Dr.
|
From page 132... ...
He currently has a project in South Africa, funded by the National Institute for Occupational Safety and Health (NIOSH) , studying the transmission of MDR TB using large numbers of guinea pigs to quantify the infectiousness of MDR TB patients and the effectiveness of various control interventions, including ultraviolet germicidal irradiation.
|
From page 133... ...
In 1999, he joined Corixa Corporation in Seattle, where eventually as Chief Scientific Officer he headed research groups focused on innate immunity, vaccine development, and molecular diagnostics. From 2001 to 2005 he was principal investigator for two grants totaling $18 million in the area of Toll-like receptor agonists and antagonists.
|
From page 134... ...
. From 1994 to 2000, he served as Assistant Director, DLS, responsible for coordinating and conducting all mycobacteriology laboratory training, performance evaluation, and research activities in addition to coordinating the Clinical Laboratory Improvement Advisory Committee.
|
From page 135... ...
Since that time he has worked as an attending physician in infectious diseases both in Washington, DC, and in South Africa, with particular interests in antimicrobial therapy, TB, and tropical diseases. Since joining the FDA in 1998, Dr.
|
From page 136... ...
She complements her research with providing care for HIV/AIDS patients in the Bronx, New York, and teaching residents on the inpatient wards. Martie van der Walt, Ph.D., Interim Director for the TB Epidemiology and Intervention Research Unit, joined TB research at the Medical Research Council South Africa in 1998.
|
From page 137... ...
After medical school, he completed a residency in internal medicine at Emory University in 1995; an EIS fellowship at CDC in 1997; and a clinical fellowship in infectious diseases, also at Emory University, in 1998. He is board certified in both internal medicine and infectious diseases.
|
From page 138... ...
His research investigates the mechanisms responsible for adverse drug interactions and means of prevention. Paul Zintl, M.P.A., is Chief Operating Officer for Partners In Health and Senior Advisor for Planning and Finance for the Program in Infectious Disease and Social Change (PIDSC)
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.